PharmaResearch, a regenerative medicine company headquartered in South Korea, has entered a strategic distribution partnership with France-based Laboratoires VIVACY, a leader in aesthetic medicine. The deal, valued at approximately €54.5 million over five years, grants VIVACY exclusive distribution rights for REJURAN®, a polynucleotide (PN)-based skin-enhancing medical device, across 22 European countries, including the UK, Germany, France, Italy, and Spain.
Science Significance
REJURAN is the first PN-based medical device approved under the EU Medical Device Regulation (MDR). Polynucleotides, derived from DNA fragments, have been clinically validated for their regenerative effects on skin, including improved elasticity, hydration, and repair of microdamage. This collaboration extends the reach of PN technology into Europe, highlighting its scientific positioning as a next-generation biomaterial for regenerative aesthetics.
Regulatory Significance
The agreement leverages REJURAN’s MDR approval, a critical regulatory milestone ensuring compliance with Europe’s stringent safety and performance standards for medical devices. This positions REJURAN as a uniquely differentiated product in a competitive aesthetic medicine market, where MDR compliance is increasingly a barrier to entry for global manufacturers.
Business Significance
Advertisement
Valued at €54.5 million over five years, the partnership combines PharmaResearch’s innovation in PN-based regenerative technologies with VIVACY’s well-established European marketing and distribution infrastructure. With VIVACY’s reach in more than 85 countries and strong commercial presence in Europe, the alliance accelerates PharmaResearch’s global expansion strategy while diversifying VIVACY’s product portfolio beyond its flagship dermal filler brands.
Patients’ Significance
For patients seeking advanced skin regeneration solutions, the introduction of REJURAN provides access to a clinically proven, minimally invasive treatment with regenerative properties. Its entry into Europe expands therapeutic options in aesthetic medicine, offering dermatologists and clinicians a premium, science-backed alternative for skin quality improvement and anti-aging interventions.
Policy Significance
This partnership illustrates the growing alignment between Asian biopharmaceutical innovation and European regulatory frameworks, supporting the EU’s goal of ensuring safe, effective, and innovative medical device access for its citizens. The deal also underscores the increasing importance of international collaborations in scaling novel medical technologies across geographies while maintaining compliance with MDR standards.
Transaction Highlights
PharmaResearch, led by CEO Jihoon Sohn, signed a €54.5 million, five-year strategic partnership with Laboratoires VIVACY for the distribution of REJURAN in 22 European countries. VIVACY will leverage its robust marketing and distribution network across Western Europe to accelerate market entry and brand visibility. REJURAN, the only PN-based medical device approved under EU MDR, will launch in major markets beginning this year, followed by a phased rollout. PharmaResearch expects the collaboration to enhance REJURAN’s global recognition and strengthen its position as a leading regenerative aesthetics brand, while VIVACY aims to enrich its aesthetics portfolio with breakthrough polynucleotide technology.
Source: PharmaResearch Press Release
